Osavampator
Overview of the drug Osavampator
| Osavampator | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Osavampator (development code TAK-653) is a pharmaceutical drug that acts as a positive allosteric modulator of the AMPA receptor. It is being investigated for its potential use in the treatment of major depressive disorder and other neurological disorders.
Mechanism of Action[edit]
Osavampator functions as a positive allosteric modulator of the AMPA receptor, which is a subtype of the glutamate receptors in the central nervous system. By enhancing the activity of these receptors, Osavampator may increase synaptic transmission and neuroplasticity, potentially leading to improved cognitive function and mood regulation.
Pharmacology[edit]
Osavampator is designed to selectively modulate the AMPA receptors without directly activating them. This selectivity is crucial as it allows for the enhancement of synaptic responses to endogenous glutamate without causing excessive excitotoxicity, which can occur with direct agonists.
Clinical Development[edit]
Osavampator is currently in the clinical trial phase, with studies focusing on its efficacy and safety in treating major depressive disorder. The drug is being evaluated for its potential to provide rapid antidepressant effects, similar to those observed with other AMPA receptor modulators.
Potential Applications[edit]
Beyond its use in major depressive disorder, Osavampator is being explored for its potential benefits in other conditions such as schizophrenia, bipolar disorder, and cognitive impairment associated with neurodegenerative diseases.
Safety and Tolerability[edit]
The safety profile of Osavampator is still under investigation. Early clinical trials suggest that it is generally well-tolerated, with a side effect profile similar to other drugs in its class. Common side effects may include headache, nausea, and dizziness.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
